BIOCODEX
17.1.2024 18:10:26 CET | Business Wire | Press release
Biocodex, a French pharmaceutical group with expertise in microbiota, women's health, orphan diseases, and My Health, a Belgian biotech company specializing in microbiota solutions, announce that they have signed a licensing agreement covering several countries in which the Biocodex Group operates, to market the DUOSPORE® dietary supplement.
My Health was founded in 2017 by Raf Dybajlo. In 2021, the company published a clinical study in The Lancet Gastroenterology & Hepatology on the efficacy of My Health’s proprietary strains, MY01 & MY02, in the treatment of functional dyspepsia (unexplained stomach complaints). The company has been marketing a range of probiotic food supplements whose formulas have been rigorously selected for their clinical efficacy, in response to growing consumer demand for solutions to digestive health, woman’s health, brain health, joint care and immune system boosting.
Through this licensing agreement, which is accompanied by the acquisition of a 20% minority stake in My Health, Biocodex intends to reinforce its leadership in microbiota and round out its range of probiotics, such as Ultra Levure® (commercialized in Belgium as Enterol®) and Alflorex®, widely known in France and around the world for the treatment of digestive disorders.
On the strength of its recognized expertise among healthcare professionals and its presence in over 100 countries worldwide, Biocodex hopes to make a success of this strategic partnership and significantly accelerate My Health international sales development.
Nicolas Coudurier, CEO of Biocodex, is delighted with the deal: "My Health and Biocodex share a common vision: we are convinced of the key role played by the microbiota in everyone's health and well-being, and believe that many ailments, particularly in the digestive sphere, can be treated by scientifically based probiotics such as those developed by My Health. I'm looking forward to supporting the development of a promising young company like My Health and continuing to play our part in raising awareness among the general public and healthcare professionals of the growing importance of the microbiota to our health and well-being."
Raf Dybajlo, CEO of My Health, expresses enthusiasm for the strategic partnership with Biocodex: “I’m honored that My Health’s innovative research and commercial success have been recognized by Biocodex. With our shared vision on the importance of microbiota solutions complemented by a joint dedication to innovation and science, we are excited to bring our solution for functional dyspepsia to many more countries, and with Biocodex as an expert in microbiota-targeted solutions, we found the perfect international partner to achieve this ambitious goal.”
About Biocodex
Biocodex, an independent, family-owned French pharmaceutical group founded in 1953, markets the probiotic strain Saccharomyces Boulardii CNCM I-745, a pioneer in the probiotic category and today No. 1 worldwide by value.
Biocodex is committed to improving the health and well-being of patients at every stage of their lives, focusing on three pillars: microbiota, women's health and orphan diseases. Its extensive product portfolio includes medicines, dietary supplements, medical devices and dermo-cosmetics.
The group has over 1,600 employees worldwide, 16 subsidiaries and is present in over 100 countries through its network of distributors; it generated sales of 501 million euros in 2022.
About My Health
My Health, an independent Belgian Biotech company, is a pioneer in advancing health through groundbreaking microbiome solutions. We are a first mover in the field of microbiome solutions for functional dyspepsia with DUOSPORE®, and have launched a diverse portfolio to effectively support people with various needs.
Our commitment is to bring innovative solutions and continue our development efforts. We work together with academic research labs in Belgium to develop new solutions for unmet needs as for example the treatment of Functional Dyspepsia and Recurrent Vulvovaginal Candidiasis (RVVC).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240117583860/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Special Olympics Airlift Takes Flight Nationwide; Dove 1 Arrives at St. Paul Downtown Airport19.6.2026 17:09:00 CEST | Press release
Approximately 130 Cessna, Beechcraft and Hawker aircraft and volunteer pilots mobilize to transport more than 800 Special Olympics athletes and coaches to the 2026 Special Olympics USA Games The 2026 Special Olympics Airlift officially took flight today as all participating Cessna, Beechcraft and Hawker aircraft, known as Doves, departed from airports across the country. Dove 1 for arrival day, a Cessna Citation Latitude generously operated by Prent Corporation, landed at St. Paul Downtown Airport (STP) carrying Special Olympic athletes and delegation members, signaling the start of Airlift arrivals for the Special Olympics USA Games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619085293/en/ Special Olympics Airlift takes flight nationwide; Dove 1 arrives at St. Paul Downtown Airport (Photo credit: Textron Aviation). The arrival signals the start of the world’s largest cumulative peacetime airlift spanning more than 40
Record Currency Management Participates in Innovative European Bank for Reconstruction and Development (EBRD) -Backed Mongolian Tugrik Transaction19.6.2026 16:53:00 CEST | Press release
Record Currency Management Ltd (RCM), subsidiary of London-listed Record plc (Record Financial Group), is pleased to announce its participation in an innovative local currency bond transaction issued by the European Bank for Reconstruction and Development (EBRD), supporting the development of Mongolia's capital markets while providing institutional investors with access to attractive frontier market opportunities. RCM is the UK currency management arm of Record Financial Group, the London-listed specialist investment group managing USD 115 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. Headquartered in London, Record has offices in Hamburg, Zurich, Zug, New York, and Hong Kong. The investment forms part of Record Financial Group's broad
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 14:29:00 CEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom